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 2
 Abstract  41 
The transcription factor NF-kB regulates the expression of a broad number of genes 42 
central to immune and inflammatory responses. We identified a new molecular network that 43 
comprises specifically the NF-kB family member NF-kB1 (p50) and miR-146a, and we show 44 
that in mast cells it contributes to the regulation of cell homeostasis and survival, while in T 45 
lymphocytes it modulates T cell memory formation. Increased mast cell survival was due to 46 
an unbalanced expression of pro- and anti-apoptotic factors, and particularly to the complete 47 
inability of p50-deleted mast cells to induce expression of miR-146a, which in the context of 48 
mast cell survival acted as a pro-apoptotic factor. Interestingly, in a different cellular context, 49 
namely human and mouse primary T lymphocytes, miR-146a and NF-kB p50 did not 50 
influence cell survival or cytokine production, but rather T cell expansion and activation in 51 
response to TCR engagement. Our data identify a new molecular network important in 52 
modulating adaptive and innate immune responses and shows how the same activation-53 
induced miRNA can be similarly regulated in different cell types even in response to different 54 
stimuli, but still determine very different outcomes, likely depending on the specific 55 
transcriptome. 56 
 57 
58 
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 Introduction 59 
 The NF-kB family of transcription factors comprises five related proteins (c-60 
Rel, RelA, RelB, NF-kB1 (p50) and NF-kB2), which are critical regulators of immunity, 61 
stress response, apoptosis and differentiation, and bind as dimers to kB sites in promoters and 62 
enhancers of a variety of genes to induce or repress transcription (reviewed in (25)). The 63 
crucial role played by this transcription factor in orchestrating immune responses is 64 
highlighted by the number of stimuli that can elicit NF-kB activation, including bacterial and 65 
viral infections, inflammatory cytokines and engagement of antigen receptors. As a 66 
consequence, dysregulation of NF-kB activity is linked to inflammatory disorders, 67 
autoimmune diseases, as well as cancer (25). Given the wide range of cellular responses 68 
regulated by NF-kB, it is not surprising that its activity must be tightly controlled at multiple 69 
levels by positive and negative regulatory elements. MicroRNAs (miRNAs) are now widely 70 
established modulators of many aspects of the immune responses (13). MiR-146a in particular 71 
is a well-studied modulator of the immune system (31), known to regulate NF-kB activation 72 
and tolerance in innate immunity (36), to act as an oncosuppressor, and to modulate T 73 
regulatory (Treg) cell functions (17, 42). 74 
 Mast cells are key effector cells in immediate hypersensitivity reactions and 75 
allergic disorders. Mice lacking the transcription factor p50 are unable to mount airway 76 
eosinophilic inflammation in the lung due to the inability to produce IL-4, IL-5 and IL-13, 77 
and to a defect in the polarization of Th2 lymphocytes (5, 29, 41). Despite the important role 78 
of mast cells in allergy and asthma and as a source of Th2-type cytokines, mast cell responses 79 
were never specifically evaluated in these mice. Here, we investigated whether p50 may have 80 
a role in regulating mast cell differentiation, homeostasis and function, as it could improve 81 
our understanding of the molecular mechanisms at the basis of mast cell-related diseases such 82 
as asthma, allergy and even mastocytosis. Specifically, we identified a role for p50, but also 83 
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for miR-146a, whose transcription was completely dependent on p50, in regulating mast cell 84 
homeostasis and cell survival. Interestingly, the same molecular network involving p50 and 85 
miR-146a acted also at the level of T lymphocytes to modulate immunological memory. 86 
Memory T cells can be broadly separated into central memory (TCM) that express the 87 
chemokine receptor CCR7 and recirculate through lymphoid organs, and effector memory 88 
(TEM) that lack CCR7 and preferentially home to nonlymphoid tissues (33). Specifically, we 89 
found that the absence of p50 (and as a consequence, of miR-146a), led preferentially to a 90 
TCM phenotype and accordingly, both human and mouse T cells forced to express higher 91 
levels of miR-146a preferentially differentiated towards a TEM -like phenotype. 92 
 Overall, we provide evidence that in the absence of p50, mast cells showed 93 
altered tissue homeostasis and survival due to increased expression of pro-survival factors 94 
such as Bcl-2 and A1, as well as reduced expression of pro-apoptotic factors such as Bax and 95 
miR-146a. The latter in particular acted in this context as a modulator of NF-kB signaling by 96 
targeting TRAF6 and reducing mast cell survival. Interestingly, in T cells miR-146a had no 97 
role in regulating T cell survival or cytokine production, but it emerged as an important 98 
regulator of T cell expansion and memory formation. 99 
 100 
101 
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 Material and Methods 102 
 Cell cultures and cell stimulation. Bone marrow-derived mast cells 103 
(BMMCs) from C57Bl/6 mice and p50-deleted mice (34) were differentiated in vitro by 104 
culturing total bone marrow cells for at least three weeks in IMDM medium containing 10% 105 
FBS, 2mM L-glutamine, 0.1mM non-essential amino acids, 50μM β-mercaptoethanol, 106 
antibiotics and 50% WEHI-3 conditioned supernatant as a source of IL-3. WEHI-3 107 
conditioned supernatant was prepared exactly as described (19). When indicated, SCF 108 
(10ng/ml, Peprotech) was also added to the cultures during mast cell differentiation. Cell 109 
differentiation was assessed by surface staining for FcεRI and Kit receptor and by toluidine 110 
blue staining as described (19). Mast cells were acutely stimulated with either 1.5μg/mL IgE-111 
anti-DNP (clone SPE7, Sigma) and 0.2μg/ml DNP-HSA (Sigma), or with 20-100μg/mL LPS, 112 
depending of the experimental conditions. In some cases, cells were stimulated with 20nM 113 
PMA and 2μM ionomycin. Primary human T lymphocytes were purified from peripheral 114 
blood and expanded as described (21). T cells were stimulated with immobilized anti-CD3 (1-115 
10μg/mL) and anti-CD28 (2μg/mL), and expanded in presence of 500U/mL rhIL-2. Blood 116 
from healthy donors was obtained from the Swiss Blood Donation Center of Basel and 117 
Lugano, and used in compliance with the Federal Office of Public Health. Mouse naïve CD8 118 
and CD4 T cells were purified using beads (Dynal or Miltenyi Biotec) from spleen and lymph 119 
nodes of OT-I, OT-II or C57Bl/6 mice, and FACS-sorted as CD62L+ CD44–. Naïve CD4 T 120 
cells were cultured in Th1/Th2 skewing conditions exactly as described (1, 22). All animal 121 
studies were performed in accordance with the Swiss Federal Veterinary Office guidelines 122 
and were approved by the Dipartimento della Sanita’ e della Socialita’ (approval numbers 123 
17/2010, 18/2010 and 03/2012). 124 
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Plasmids, lentiviral and retroviral transductions. The control lentiviral vectors 125 
were previously described and expressed either an shRNA against luciferase (shLuc), a non-126 
targeting hairpin (NT) or GFP alone (18). The 394bp PCR fragment encompassing the pre-127 
miR-146a genomic sequence was cloned using standard cloning techniques. Depending on 128 
the experimental conditions, transduced cells were either selected with puromycin (2μg/mL 129 
for two days) or FACS-sorted for GFP expression. To optimize transgene expression, the 130 
same miR-146a or control insert was driven by the spleen focus-forming virus promoter 131 
(SFFVp) for transductions of mast cells, and by the EF1alpha promoter for transductions of 132 
human T lymphocytes. Lentiviral particles were produced exactly as described and used at a 133 
multiplicity of infection of ~60 (19, 44). Retroviral particle were generated by transient 134 
transfection of Phoenix cells as previously described (24). 135 
 qRT-PCR. Total RNA was extracted using TRIzol reagent (Invitrogen). To 136 
analyze miRNA expression, qRT-PCR was performed using a miRNA reverse transcription 137 
kit and TaqMan miRNA assays from Applied Biosystems, following exactly the 138 
manufacturer’s instructions. To analyze Bcl-2 family member expression, total RNA (1μg) 139 
was reverse transcribed using the iScript kit (Bio-Rad), before PCR amplification with the 140 
following primers: bcl2 FW: 5’-TTCGCAGCGATGTCCAGTCAGCT; bcl2 RV: 5’-141 
TGAAGAGTTCTTCCACCACCGT; A1 FW: 5’-GATTGCCCTGGATGTATGTGCTTA; A1 142 
RV: AGCCATCTTCCCAACCTCCATTC; bcl-XL FW: 143 
CAGTGCCATCAATGGCAACCCATC; bcl-XL RV: 5’-144 
CGCAGTTCAAACTCATCGCCTGC; bax FW: 5’-ACTGGACAGCAATATGGAGCTG; 145 
bax RV: 5’-CCCAGTTGAAGTTGCCATCAG. β-actin was used as an endogenous control. 146 
 Apoptosis and proliferation. For cell death analysis, mast cells were washed 147 
extensively to remove all IL-3 and/ or SCF from the culture medium and were either left 148 
resting or were stimulated with IgE and antigen. Apoptosis was evaluated using the 149 
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AnnexinV-PE apoptosis kit (BD Pharmingen) following manufacturer’s instructions. For 150 
thymidine incorporation assays, 1x105 mast cells were stimulated for 24h, and in the last 16h 151 
of incubation, 1µCi/mL of [3H]thymidine (GE Healthcare) was added to the cultures. Cells 152 
were then collected and levels of thymidine incorporation were evaluated with a scintillation 153 
beta-counter. 154 
 Degranulation assay. Mast cell degranulation was assessed as described (18). 155 
Briefly, 5x104 cells were resuspended in 50μL OptiMEM, 1% FBS and stimulated for 1h with 156 
either PMA and ionomycin or IgE-antigen complexes. The supernatant was collected and the 157 
cell pellet was lysed in 50μL of 0.5% Triton-X100 in OptiMEM, 1% FBS. The β-158 
hexosaminidase substrate (4-nitrophenyl N-acetyl-β-D-glucosaminidate (Sigma)) was then 159 
added to both the cell lysates and supernatants (50μL of 3.8mM solution). After incubation 160 
for 2h at 37°C, the reaction was stopped with 90μL glycine 0.2M, pH 10.7, and the 161 
absorbance was read at 405nm. The percentage of degranulation was calculated as the ratio 162 
between the absorbance of supernatants and the total absorbance of supernatants and cell 163 
lysates. 164 
 Intracellular cytokine staining. Cells were stimulated with either PMA and 165 
ionomycin, IgE and antigen complexes, or LPS for 3-5h, with addition of 10μg/mL brefeldin-166 
A in the last 2h of stimulation. The cells were then fixed with 4% paraformaldehyde and 167 
permeabilized in 0.5% saponin/ 1% BSA prior staining with fluorescent anti-cytokine 168 
antibodies (eBioscience) and FACS analysis.  169 
 Western Blots and Immunofluorescence staining. For Western blots, total 170 
protein extracts were prepared by direct lysis of the cells in Laemmli sample buffer. Samples 171 
were separated on 12% SDS-polyacrylamide gels and immune-detection was performed with 172 
antibodies against NF-kB p50 (NLS), TRAF6 (H-274) and, as a loading control, β-Tubulin 173 
(H-235) (all from Santa Cruz Biotechnologies). Quantification was performed with a 174 
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biomolecular imager (ImageQuant LAS 4000). For immunofluorescence staining, tissue 175 
slides of paraffin-embedded organs from wild-type and p50-deleted mice were de-176 
paraffinized, rehydrated and stained with 2μg anti-mast cell tryptase antibody (FL-275, Santa 177 
Cruz Biotechnologies), followed by an anti-rabbit AlexaFluor-594 secondary antibody 178 
(Invitrogen). Nuclei were counter-stained with DAPI. Images were captured with a Nixon 179 
Eclipse E800 microscope and analyzed with the Openlab software (Improvision). 180 
 Passive cutaneous anaphylaxis (PCA) and peritoneal lavages. For passive 181 
cutaneous anaphylaxis experiments, 1x106 differentiated BMMCs were injected intradermally 182 
(i.d.) in the ear pinna of mice lacking mast cells (KitW-sh/W-sh, Jackson Laboratory) (8). Four 183 
weeks after reconstitution, transferred mast cells were sensitized by i.d. injections of IgE-anti-184 
DNP (1.5μg/mL), and challenged 24h later with intravenous (i.v.) injections of 250μg/mL 185 
DNP-HSA together with 5mg/mL Evans-blue dye to assess extravasation. Mice were 186 
sacrificed 30min after challenge and the blue dye was extracted from the tissues by incubation 187 
in formamide at 63°C O/N. Intensity of the blue dye (correlating with the extent of 188 
extravasation and therefore mast cell activation) was measured spectrophotometrically 189 
(OD600). Presence of mast cells in the reconstituted ears was assessed by toluidine-blue 190 
staining of paraffin-embedded ears. For peritoneal lavages, the total number of recovered cells 191 
was assessed by manual counting, while the percentage of mast cells was evaluated by surface 192 
staining for Kit and FcεRIα and FACS analysis. 193 
 Transfection of naïve T cells. Sorted naïve (CD4+ CD8– CD62Lhi CD44lo) T 194 
cells were transfected with Amaxa mouse T cells nucleofector kit following manufacture’s 195 
instructions, using program X-01. Cells were rested for at least 3h after transfection and prior 196 
stimulation with plate-bound anti-CD3 and anti-CD28 for 48h. 197 
 Adoptive transfer of mouse T cells and immunization. Sorted CD8 or CD4 198 
naïve T cells were obtained from spleen and lymph nodes of C57Bl/6, OT-I or OT-II mice 199 
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and injected (1x106 cells/ mouse) in C57Bl/6 recipients. Mice were then challenged sub-200 
cutaneously with CFA-OVA and naïve, effector and memory cells were obtained from the 201 
spleen and draining lymph nodes 4 days (effector) or two weeks (memory) after challenge, 202 
and they were sorted in the different subsets based on the expression of CD4, CD8, CD62L, 203 
CD44 and CD127. 204 
 CFSE labeling. CFSE labeling was performed using a CellTrace cell 205 
proliferation kit (Invitrogen). Briefly, 1x106-107 naïve T cells (human or mouse) were labeled 206 
with 5μM CFSE for 8min at 37°C prior extensive washing and antigenic stimulation. 207 
 Statistical analysis. Results are expressed as a mean ± s.d. or s.e.m. 208 
Comparisons were made using the unpaired t-test and the GraphPad Prism Software. 209 
 210 
  211 
212 
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 Results 213 
 Elevated numbers of mast cells in the absence of NF-kB p50. Mice lacking 214 
p50 (p50ko) are unable to mount airway eosinophilia inflammation due to the inability to 215 
produce IL-4, IL-5 and IL-13, and to a defect in the polarization of Th2 lymphocytes (5, 29, 216 
41). Since mast cells are master effector cells in asthmatic and allergic responses, we 217 
evaluated whether such asthma-resistant phenotype could be partially due to a defect in mast 218 
cell development or function. First, we evaluated the numbers of mast cells in the tissues of 219 
p50ko animals. In the peritoneal lavages of control and p50ko mice, the total number of cells 220 
and the percentage of mast cells were assessed respectively by manual counting and by 221 
surface staining for FcεRIα and Kit. Surprisingly, the percentage of mast cells recovered from 222 
the peritoneal cavity in the absence of p50 was significantly augmented  (p<0.0002) 223 
compared to control animals (Figure 1A). The percentage of Gr-1+ cells was also 224 
significantly increased in the peritoneal lavage of p50ko mice relative to controls. A similar 225 
kind of increase in the presence of mast cells was also observed in the small intestine of 226 
p50ko animals compared to C57Bl/6 mice, as assessed by immunofluorescence staining using 227 
two different mast cell markers (Tryptase or Kit) (Figure 1B). These results showed an overall 228 
increase in mast cells in the tissues of p50ko animals, without however revealing any 229 
alteration in the homing properties of these cells. Indeed, mast cells were found in all tissues 230 
and compartments where they are normally present, but not in organs, like the spleen or liver, 231 
where they are usually not found (not shown). Having ruled out that the asthma-resistant 232 
phenotype of p50ko animals does not correlate with the number of mast cells in these mice, 233 
and considering that mast cells are able to produce very high amounts especially of IL-13, we 234 
assessed the ability of these cells to respond to a variety of stimuli. 235 
  236 
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 Reduced cytokine production in mast cells lacking p50. Similarly to 237 
controls, in vitro differentiated, bone marrow-derived p50ko mast cells were homogenously 238 
FcεRIα+ Kit+, expressed granzyme B and mMCP5 (not shown), and looked phenotypically 239 
normal as assessed by toluidine blue staining (Supplementary Figure 1A). Since the 240 
percentage of mast cells was increased in the tissues of p50ko animals relative to C57Bl/6 241 
mice, we asked whether the absence of p50 could favor cell proliferation. As assessed by 242 
thymidine incorporation assay, p50ko cells proliferated similarly to the controls in all 243 
condition tested (Figure 1C). Next, we evaluated whether the impaired Th2 responses 244 
observed in these mice could be partially explained by an altered ability of mast cells to 245 
perform their effector functions (degranulation, cytokine production) in response to acute 246 
stimulation. The extent of mast cell degranulation was assessed both in vitro, by measuring 247 
release of β-hexosaminidase from cytoplasmic granules upon stimulation (18), and in vivo, by 248 
transferring mast cells into mast cell-deficient recipient mice (KitW-sh/W-sh) and performing 249 
passive cutaneous anaphylaxis (PCA) experiments. Even in the absence of p50 mast cells 250 
degranulated normally in response to IgE crosslinking or PMA and ionomycin stimulation, 251 
both in vitro and in vivo (Figure 1D-E). In PCA experiments, efficient mast cell reconstitution 252 
of the ear pinna was confirmed by toluidine blue staining of paraffin-embedded tissue 253 
sections (Figure 1F).  254 
 Next, we evaluated the ability of p50ko mast cells to produce cytokines, and 255 
we focused mostly on cytokines, such as IL-13, that are highly expressed by mast cells and 256 
have essential and non-redundant roles in allergy and asthmatic responses (10, 23, 38). 257 
Control and p50ko cells were stimulated with either LPS or IgE crosslinking, and expression 258 
of IL-6, TNF-α and IL-13 was assessed by intracellular cytokine staining (Figure 2A-C). 259 
Interestingly, mast cells lacking p50 showed reduced cytokine production in response to both 260 
LPS and IgE-Ag complexes, which was not due to altered expression of the surface receptors 261 
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FcεRI or TLR4 (Figure 2D). Reduced cytokine expression was particularly evident for IL-13, 262 
which is the cytokine necessary and sufficient for asthmatic responses in models of 263 
experimental asthma (10, 38) (Figure 2B-C). Despite the increased number of mast cells in 264 
the tissues of p50ko animals, reduced IL-13 production from p50ko mast cells may therefore 265 
contribute to the asthma-resistant phenotype and overall lack of eosinophilia and Th2 266 
responses observed in these mice. However, our data so far could not explain the increased 267 
mast cell numbers observed in the tissues of p50ko mice, which is what we set out to 268 
investigate next. 269 
 270 
Increased survival in the absence of p50 correlates with increased expression of 271 
anti-apoptotic genes. Given the increased number of tissue mast cells despite the normal 272 
proliferation capacity, we investigated whether p50ko mast cell were significantly affected in 273 
their ability to survive in response to IgE crosslinking and/ or withdrawal of essential 274 
cytokines. The essential survival factors IL-3 and/ or SCF were removed from the culture 275 
medium, with or without concomitant stimulation with IgE, which are known to provide a 276 
survival signal for mast cells, by inducing anti-apoptotic factors (14, 39). In all conditions 277 
tested p50ko cells showed a consistently increased ability to survive compared to the controls 278 
(Figure 3A-C). As expected, stimulation with IgE partially rescued control cells from 279 
apoptosis, but this effect was much more pronounced in the absence of p50 (Figure 3C). To 280 
get an insight in the molecular mechanism that could explain such enhanced survival, we 281 
evaluated the expression of candidate pro- and anti-apoptotic genes. Indeed, NF-kB binding 282 
sites have been identified in promoters and enhancers of a number of inducible genes 283 
involved in cell death, including Bcl-2, A1 and Bcl-XL (14, 39). In particular, Bcl-2 is a 284 
known regulator of IL-3 withdrawal-dependent apoptosis, while A1 is a specific regulator of 285 
IgE-dependent survival in mast cells (14, 39). We therefore investigated whether these factors 286 
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may be involved in regulating survival in the absence of p50. To this end, p50ko and control 287 
cells were either left resting or were stimulated with either IgE crosslinking or LPS, after 288 
which expression of pro- and anti-apoptotic gene candidates was assessed by qRT-PCR 289 
(Figure 3D-G). Interestingly, both bcl2 and A1 were upregulated in cells lacking p50. Such 290 
upregulation was already evident at basal levels, but it became even more pronounced upon 291 
stimulation with IgE-DNP or LPS (Figure 3D-E). Expression of another pro-survival factor, 292 
bcl-XL, was slightly diminished in p50ko cells (Figure 3F), as well as the expression of the 293 
pro-apoptotic gene bax (Figure 3G). Since Bcl-2 and especially A1 were already shown to be 294 
involved in regulating mast cell survival, it is likely that the overall net increase of pro-295 
survival factors is at the basis of the observed enhanced survival of p50ko cells. Our data 296 
therefore show that p50ko mast cells exhibit increased survival in response to a variety of 297 
stimuli, and that such enhanced survival is likely due to a profound alteration in the balance 298 
between pro- and anti-apoptotic factors, with the latter being overall favored. 299 
  300 
 MiR-146a regulates mast cells survival, but not cytokine production or 301 
LPS desensitization. Since miRNAs are known to be involved in the regulation of a variety 302 
of cell functions, we assessed whether they might also be involved in regulating the enhanced 303 
survival and reduced cytokine production observed in p50ko mast cells. We assessed in 304 
particular expression of two miRNAs (miR-146a and miR-221) that we found to be inducible 305 
in mast cells and to be dependent on NF-kB (18, 20, 36). P50ko and control mast cells were 306 
either left resting or were stimulated with PMA and ionomycin for 24h, after which 307 
expression of miR-146a and miR-221 was assessed by qRT-PCR. MiR-27a expression was 308 
also measured as a control since it should not change upon stimulation of mast cells. 309 
Strikingly, p50ko mast cells showed specifically impaired expression of miR-146a in 310 
response to stimulation in all conditions tested, including PMA and ionomycin, IgE 311 
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crosslinking or LPS stimulation (Figure 4A-B), indicating that p50 is indeed absolutely 312 
required for the expression of this miRNA. Vice versa, expression of miR-221, also known to 313 
be inducible upon mast cell stimulation in a NF-kB-dependent manner (20), was comparable 314 
between p50ko cells and controls, indicating that for miR-221, but not miR-146a expression, 315 
the lack of p50 can be compensated by the presence of other NF-kB subunits. 316 
 Since p50ko cells are completely unable to induce miR-146a expression, and it 317 
is known that miR-146a is itself a regulator of NF-kB activation (36), we asked whether at 318 
least part of the phenotype observed in mast cells in the absence of p50 could be due to the 319 
inability of these cells to induce miR-146a expression. We therefore transduced mast cells 320 
with either a control lentiviral vector (shLuc, expressing an irrelevant hairpin), or a vector 321 
expressing miR-146a, and we asked whether miR-146a expression led to altered survival in 322 
mast cells. Indeed, mast cells transduced with miR-146a showed consistently increased cell 323 
death compared to control cells, even when cultured in medium supplemented with all 324 
survival factors (Figure 4C-D). As a control, to confirm that our lentivirally-derived miR-325 
146a was indeed properly functional, we evaluated levels of expression of the known miR-326 
146a target, Traf6 (36). Western blot analysis showed a significant decrease in Traf6 327 
expression whenever miR-146a was expressed, in both p50ko and control cells (Figure 4E). 328 
Interestingly, forced miR-146a expression led to an only modest reduction of bcl2 expression 329 
in p50ko cells, indicating that although miR-146a works in the same pathway as p50, forced 330 
miR-146a expression is not sufficient to completely compensate and revert the phenotype 331 
induced by the lack of p50 (Figure 4F). Along the same line, we did not observe any 332 
particular effect of miR-146a on IL-6 and TNFα expression (Figure 4G).  333 
 Repeated stimulation of cells can result in loss of responses. MiR-146a is 334 
known to regulate tolerance to LPS in macrophages (36), and given the inability of p50ko 335 
mast cells to induce miR-146a expression in response to LPS, we assessed whether these cells 336 
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might be impaired in their responses to sequential stimulations with LPS. However, mast cells 337 
lacking p50 showed a reduction in cytokine production in response to acute LPS stimulation, 338 
but responded similarly to control cells, becoming unresponsive to subsequent stimulations 339 
with LPS (Supplementary Figure 1B-C), indicating that such LPS-dependent 340 
unresponsiveness in mast cells is not strictly dependent on miR-146a.  341 
  342 
 MiR-146a is highly expressed in the T cell memory compartment from 343 
both human and mouse. Since we previously reported that miR-146a is differentially 344 
expressed between Th1 and Th2 T cell subsets in the mouse (22), we asked whether the novel 345 
molecular network we identified in mast cells, involving miR-146a and p50, could also be at 346 
play in regulating T lymphocyte polarization, which was also shown to be altered in mice in 347 
the absence of p50 (5). In mouse CD4 T cells we found that miR-146a was indeed expressed 348 
at higher levels in Th1 cells compared to Th2 (Figure 5A), however, it remained inducible in 349 
both T cell subsets upon restimulation, with high strength of TCR stimulation correlating with 350 
high levels of miR-146a expression and also with high and sustained number of cell cycles, as 351 
assessed by CFSE dilution (Figure 5B). We therefore hypothesized that miR-146a could have 352 
a role in regulating T cell activation and expansion rather than T cell polarization. In line with 353 
this hypothesis, we found that miR-146a expression was consistently elevated in the effector 354 
and memory compartment (TEM and TCM) in both CD4 and CD8 murine T cells (Figures 5C-355 
D). Similarly to CD4 T cells, naïve CD8 T cells activated in vitro with anti-CD3 and anti-356 
CD28 showed increased expression of miR-146a (Figure 5D, left panel). Next, we reasoned 357 
that if miR-146a is an important regulator of T cell polarization and/ or activation, such 358 
process should be conserved also in human T cells. Human TH1 and TH2 cells, either 359 
differentiated in vitro or separated ex vivo from peripheral blood, did not show any 360 
differential expression of this miRNA (Figure 5E and Supplementary Figure 2A). However, 361 
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similarly to mouse T cells, resting human CD4 lymphoctyes retained the ability to activate 362 
expression of miR-146a once restimulated and even more importantly, miR-146a was 363 
expressed at high levels in memory T cells isolated ex vivo from peripheral blood (Figure 5F-364 
G). These data indicate that miR-146a is unlikely to play a major role in T cell polarization in 365 
both human and mouse (except probably Treg cells in which it is expressed at high levels 366 
((17) and Supplementary Figure 2A), but point towards a role in regulating lymphocyte 367 
activation and/or in the establishment of immunological memory.  368 
  369 
 MiR-146a influences cell expansion, but not cell death of primary human 370 
lymphocytes. To further investigate the role of miR-146a specifically in human lymphocytes, 371 
and to assess whether it could modulate cell survival, similarly to mast cells, human CD4 T 372 
cells were lentivirally transduced to express GFP, alone or in combination with miR-146a 373 
(Figure 6A). Levels of miR-146a in transduced cells were overall lower or comparable to the 374 
physiological levels of endogenous expression observed in lymphocytes upon TCR 375 
stimulation (Supplementary Figure 2B). However, we found that primary human T cells 376 
expressing miR-146a did not show any significant alteration in Fas-mediated cell death or in 377 
CD95 expression or in the ability to survive in response to withdrawal of IL-2 378 
(Supplementary Figure 2C-D and data not shown). Moreover, we observed no significant 379 
effect of miR-146a on IL-2, IFN-γ or IL-4 cytokine production (Supplementary Figure 2E and 380 
data not shown). 381 
 While we did not observe any effect on cell death, memory human T cells 382 
expressing miR-146a showed increased expansion after restimulation with anti-CD3 and anti-383 
CD28 (Figure 6B). Specifically, cells expanded similarly up to ~day 4-5 after stimulation, 384 
regardless of miR-146a expression, but miR-146a-expressing cells continued to expand more 385 
vigorously then control cells in the subsequent days, an effect that was especially evident in 386 
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the absence of exogenous IL-2, indicating that this miRNA could act directly in response to 387 
TCR stimulation to favor cell expansion (Figure 6B). The fact that cytokine production was 388 
largely unaffected by miR-146a in all conditions tested, ruled out the possibility that miR-389 
146a-expressing cells could sustain their own proliferation through increased IL-2 production. 390 
We also performed adoptive transfer experiments in which mouse OT-II naïve T cells 391 
transfected with either miR-146a mimic or non-targeting control were transferred into a 392 
recipient mouse. A few days after challenge with OVA, both the draining lymph node and the 393 
spleen showed a slightly higher percentage of transferred cells whenever miR-146a was 394 
present, suggesting increased expansion abilities following challenge (Supplementary Figure 395 
3A-B). Finally, in a different experimental setting, human naïve T cells were transiently 396 
transfected with a miR-146a mimic and then stimulated with allogeneic PBMC, after which 397 
the percentage of activated T cells was assessed. Consistently with the results obtained using 398 
lentiviral vectors, we observed a reproducible, albeit small, increase in the percentage of 399 
activated cells whenever miR-146a was present (Supplementary Figure 3C). 400 
  401 
MiR-146a regulates CCR7 expression. While IL-2 does not significantly contribute 402 
to the initial cycling of antigen-stimulated T cells, it is nevertheless necessary for the 403 
successful generation of memory responses (12). Indeed, the IL-2 signal strength has been 404 
shown to contribute to the differentiation of murine CD8 TEM and TCM (28). In our culture 405 
system, the absence of IL-2 uncovered a TEM-like phenotype, with inability to sustain CCR7 406 
expression and expansion after TCR stimulation (Figure 6C-D). Interestingly, miR-146a 407 
expression determined a reduction of CCR7 expression in all conditions tested, indicating that 408 
not only miR-146a contributed to T cell expansion upon TCR stimulation, but it may also 409 
modulate the establishment of a TEM-like phenotype (with reduced CCR7 expression) in 410 
primary human lymphocytes (Figure 6E). Since most of our experiments so far were 411 
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performed on memory TH1, TH2 and TH17 cells subsets isolated from peripheral blood and 412 
restimulated in vitro, to better assess the effect of miR-146a during the first antigenic 413 
stimulation of naïve T cells, we lentivirally transduced human naïve T cells freshly isolated 414 
from peripheral blood to express miR-146a. Three days after transduction GFP+ cells were 415 
sorted and stimulated with plate-bound anti-CD3 and anti-CD28, and five days after 416 
stimulation total RNA was extracted and levels of expression of miR-146a and CCR7 were 417 
assessed by qRT-PCR. As a control, we also measured expression of the known miR-146a 418 
target TRAF6. Similarly to memory cells, naïve T cell expressing miR-146a showed reduced 419 
CCR7 and TRAF6 expression (Figure 6F). However, the reduction in CCR7 expression was 420 
very selective, as we could not observe any alteration in the expression levels of CD25, 421 
CD45RA, CD45RO, CD62L or CD127 (data not shown). Moreover, such effect of miR-146a 422 
is unlikely to be exerted directly on CCR7, which is not a predicted target for this miRNA 423 
(16). 424 
It was shown that mice with a T cell-specific deletion of TRAF6 mounted robust CD8 425 
effector responses, but had a profound defect in their ability to generate memory cells (26). 426 
To further demonstrate that TRAF6 is indeed a target for miR-146a in primary T lymphocytes 427 
we also performed reporter assay experiments using the 3’untranslated region (3’UTR) of 428 
TRAF6, and found that it was efficiently targeted by miR-146a in both Jurkat cells and 429 
primary murine Th2 cells (Supplementary Figure 3D). Our data point towards a role for miR-430 
146a in regulating human T cell responses and memory formation possibly through the 431 
modulation of TRAF6 expression. 432 
 433 
Dysregulated T cell memory formation in the absence of the p50/ miR-146a 434 
molecular circuitry. Since we showed that miR-146a dysregulation could influence T cell 435 
memory formation, leading to a CCR7lo, TEM-like phenotype, and we also found that in mast 436 
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cells miR-146a expression was fully dependent on p50 expression, we looked into T cell 437 
activation and memory formation in the absence of p50 (and therefore in the absence also of 438 
miR-146a).  First, we assessed whether miR-146a expression was indeed impaired in the 439 
absence of p50 also in T lymphocytes. Naïve CD8 and CD4 T cells were isolated from p50-440 
deleted animals and were stimulated in vitro with plate-bound anti-CD3 and anti-CD28 for 5 441 
days, after which they were either left resting or were restimulated with PMA and ionomycin 442 
(P+I) for 6h. Similarly to mast cells stimulated with either IgE or LPS, T cells (both CD4 and 443 
CD8) lacking p50 were completely unable to induce miR-146a expression, neither upon TCR 444 
engagement of naïve T cells, nor upon restimulation (Figure 7A-B). Moreover, there was no 445 
significant difference between p50-deleted T cells and controls in IFNγ, IL-4 and IL-2 446 
cytokine production, as assessed by intracellular cytokine staining (data not shown). We 447 
therefore analyzed the memory compartment of p50-deleted mice ex vivo. As shown in Figure 448 
7C, in the absence of p50, both the CD4 and especially the CD8 T cell compartment showed a 449 
striking increase in the TCM compartment, and a reduction of effector cells, even in the 450 
absence of any challenge. Importantly, sorted p50ko naïve T cells differentiated in vitro for 5 451 
days also showed a TCM-like phenotype, with high expression of CD44 and CD62L and 452 
intermediate expression of CD25 (Figure 7D), indicating that the absence of p50 and miR-453 
146a intrinsically favors naïve T cell differentiation to a TCM phenotype, independently of 454 
thymic development. However, forced expression of miR-146a in p50ko CD4 T cells by 455 
either retroviral transduction or transient transfection could not rescue the phenotype observed 456 
in the absence of p50 (Figure 7E-G), indicating once again that miR-146a alone is not able to 457 
fully compensate for the lack of a transcription factor, at least in our in vitro experimental 458 
settings.  459 
  460 
 461 
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  462 
 Discussion  463 
 NF-kB is involved in regulating many aspects of cellular activity during an 464 
immune response, and activation of this transcription factor by receptors of the innate and 465 
adaptive immune response is essential for host defense (reviewed in (25)). Almost all danger-466 
sensing receptors activate NF-kB to mediate effector functions, however, NF-kB-driven 467 
responses must be promptly terminated once danger is eliminated, as aberrant NF-kB activity 468 
can directly lead to uncontrolled tissue damage and disease (reviewed in (30)). 469 
 Here, we found that the absence of one specific NF-kB family member, p50, 470 
improved mast cell survival in response to a variety of signals. The underlying mechanism for 471 
such enhanced survival involved increased expression of pro-survival factors such as Bcl-2 472 
and A1, as well as reduced expression of pro-apoptotic factors such as Bax and miR-146a, 473 
which in this context acted as a pro-apoptotic factor and as a modulator of NF-kB signaling 474 
by targeting Traf6. In our current working model NF-kB activation in mast cells can occur as 475 
a result of FcεRI crosslinking or TLR4 engagement leading to nuclear translocation of p65-476 
p50 heterodimers that activate transcription of both anti-apoptotic factors (such as bcl2 and 477 
A1) as well as of pri-miR-146a, which acts as a negative regulator of NF-kB activation 478 
(Supplementary Figure 4A-C). In the absence of p50, not only some survival factors are 479 
strongly upregulated, but the negative feedback on NF-kB activation is lost, as miR-146a 480 
cannot be expressed, reinforcing the positive survival signal. The fact that in the context of 481 
mast cell survival miR-146a acts as a pro-apoptotic factor is also highlighted by the fact that 482 
forced expression of miR-146a leads to increased cell death. 483 
 What remains to be investigated is the mechanism by which NF-kB p50 may 484 
act as a positive regulator of some genes (namely miR-146a, for which p50 is essential), and 485 
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as a negative regulator of other genes (namely Bcl-2 and A1, whose expression is increased in 486 
both basal and activated conditions in the absence of p50). One possible explanation concerns 487 
the formation of compensatory heterodimers in the absence of p50 with an altered pattern of 488 
binding and activation. Indeed, the unique DNA-binding properties of distinct NF-kB dimers 489 
influence the selective regulation of NF-kB target genes. NF-kB dimers can be separated in 490 
three distinct DNA-binding classes based on their DNA-binding preferences: p50 or p52 491 
homodimers, heterodimers, c-Rel or RelA homodimers (35). Clearly, sites that are normally 492 
preferentially bound by p50 homodimers could become ‘free’ to be bound by other NF-kB 493 
family members in the absence of p50, altering regulation of transcription at these specific 494 
sites. Our initial data in this direction show that p65 nuclear translocation is normal in mast 495 
cells in the absence of p50, however its overall expression is slightly reduced (Supplementary 496 
Figure 1D). We have yet to uncover specific differences in promoter binding, which will be 497 
the topic of future work. Another possibility is that by lacking a transactivating domain, p50 498 
homodimers may negatively regulate expression of bcl2 and A1 in resting conditions, which 499 
is overcome by other activating heterodimers upon activation. For example, negative 500 
regulation by p50 homodimers has been reported to correlate with repression of NF-kB-501 
driven transcription in tolerant T cells (9), and tolerance to LPS in monocytes has been shown 502 
to involve LPS-dependent mobilization of NF-kB with a predominance of p50 homodimers 503 
(43). P50 homodimers are also known to be nuclear even in the absence of stimulation, which 504 
may explain the increased expression of Bcl-2 and A1 at basal levels in the absence of p50 (2, 505 
32). On the other hand, miR-146a expression remained exquisitely dependent on p50 in all 506 
conditions tested. Further experiments will elucidate the exact molecular mechanism 507 
responsible for the enhanced survival observed in mast cells in the absence of p50, and this 508 
will be the topic of future work. 509 
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 As for the observed increase of mast cells in the tissues of p50ko animals, the 510 
possibility remains that such alteration may arise from an increased ability of hematopoietic 511 
stem cells (HSC) in the bone marrow to differentiate more promptly to mast cells and/ or in 512 
general to the myeloid lineage. The increased number of mast cells could therefore be a 513 
composite effect of increased differentiation from stem cells, combined with a cell-intrinsic 514 
ability of the cells to survive in response to a variety of stimuli. A detailed analysis of HSC 515 
differentiation in the absence of p50 will surely provide new insights on the role of this 516 
transcription factor in hematopoietic differentiation, particularly to the myeloid lineage.  517 
 As opposed to mast cells, in T lymphocytes miR-146a did not regulate cell 518 
death, but rather influenced T cell activation upon TCR engagement. It is interesting to notice 519 
that in accordance with published data (4), we found that ectopic expression of miR-146a in 520 
Jurkat cells led to a mild reduction in apoptosis (data not shown). However, primary cells 521 
expressing miR-146a did not show any significant alteration in Fas-mediated cell death or in 522 
CD95 expression. Such discrepancy may be due to the fact that while in Jurkat cells 523 
activation-induced cell death (AICD) can be completely cell autonomous, primary T 524 
lymphocytes undergo AICD by making contact with their activated neighbors, resulting in 525 
‘fratricide’ rather than ‘suicide’ (3, 6, 7). Alternatively, miR-146a may have roles that vary in 526 
the different cell types depending on the type and relative abundance of mRNA targets that 527 
constitute the transcriptome of that specific cell, as we have shown for mast cells and T 528 
lymphocytes. We therefore propose a model in which miR-146a upregulation upon TCR 529 
stimulation contributes to the overall strength of signal arising from the TCR, by favoring cell 530 
activation and cell expansion, and by modulating the establishment of immunological 531 
memory, in particular by favoring a CCR7lo, TEM-like phenotype (Supplementary Figure 4D). 532 
 Importantly, it has recently been shown that mice lacking p50 have altered 533 
negative selection in the thymus and develop a population of single-positive CD8 thymocytes 534 
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with memory T cell-like properties that populate peripheral immune organs (11). Here, we 535 
were able to show that in the absence of p50 even highly purified naïve CD4 and CD8 T cells 536 
stimulated in vitro preferentially acquired a TCM-like phenotype, with high CD62L and 537 
moderate expression of CD25. While this effect is clearly dependent on the absence of p50, 538 
we speculate that it might also be due, at least in part, to the inability of these cells to express 539 
miR-146a in response to TCR stimulation. It would be interesting to estimate the proportion 540 
of the effect of a given transcription factor, such as NF-kB p50, that goes through the altered 541 
expression of a specific miRNA, like miR-146a. However, is has to be noted that miR-146a-542 
deleted mice showed normal proportions of CD4 and CD8 cells both in the thymus and in the 543 
periphery (17), and even in our hands in mast cells, miR-146a was only partially able to 544 
compensate for the lack of p50, indicating that at least in this case, the effect of a transcription 545 
factor remains predominant to that of the miRNA. Moreover, some of our data are also in line 546 
with a very recent publication showing that miR-146a also controls the resolution of T cell 547 
responses in mice and its absence leads to increase survival through modulation of bcl2 548 
expression (40). 549 
 As for targets of miR-146a, we found that TRAF6 was clearly targeted by this 550 
miRNA both in mast cells and primary T lymphocytes from human and mouse, similarly to 551 
what has been extensively shown for macrophages and other cell types (36). However, other 552 
targets for miR-146a have been suggested (17, 31), and TRAF6 may not be the only or the 553 
most relevant target for this miRNA in these particular cell context: for example, we showed 554 
for miR-221 that although some specific genes are targeted by this miRNA in mast cells, the 555 
effect of miR-221 does not go predominantly through these targets, and bioinformatics 556 
analysis clearly showed that miR-221 affected a few hundred primary and secondary targets 557 
(18). Nevertheless, in an attempt to phenocopy the effects of miR-146a, we attempted knock-558 
down experiments for TRAF6 in primary human T cells using siRNAs. While unfortunately 559 
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we were so far unable to draw definite conclusions from these experiments, it remains to be 560 
noted that mice with a T cell-specific deletion of traf6 mounted robust CD8 effector 561 
responses, but had a profound defect in their ability to generate memory cells (26), therefore 562 
resembling the increased TEM-like phenotype of our miR-146a-expressing cells. Moreover, 563 
Fas-mediated apoptosis in the absence of Traf6 was normal, and cells showed increased 564 
proliferation in response to TCR stimulation, again similarly to what we observed in miR-565 
146a-expressing cells (15). 566 
 Finally, as for the fact that miR-146a is expressed at higher level in Th1 567 
murine lymphocytes compared to Th2 (22), we think that such differential expression might 568 
be related to the strength of signal that favors one or the other phenotype, with stronger 569 
stimulation favoring Th1 responses (37). Further supporting this possibility, it has been 570 
suggested that strong stimulation is needed for commitment to TEM cells, whereas weaker 571 
stimulation favors the generation of less-committed TCM cells (27), indicating that miR-146a 572 
might play an important role in lowering the strength of signal required for full T cell 573 
activation and therefore mimic stronger TCR engagement resulting in increased activation 574 
and generation of TEM. Alternatively, IL-4 and/ or IL-12 signaling may also contribute to 575 
modulate expression of miR-146a in conjunction with TCR stimulation, a possibility that 576 
remains to be investigated. However, it has to be noted that we found no significant difference 577 
in miR-146a expression in human TH1, TH2 and TH17 cells, indicating that cytokine 578 
signaling may not be at play (Supplementary Figure 2A). Similarly to the mouse (17), this 579 
miRNA was instead expressed at very high levels in human Tregs. 580 
 Overall, our findings indicate that NF-kB p50 acts in a cell-autonomous 581 
manner in differentiated mast cells to favor survival in response to withdrawal of essential 582 
cytokines or antigenic stimulation, while in T lymphocytes it enhances TCR-dependent 583 
activation and modulates memory formation. This novel molecular network comprising 584 
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specifically p50 and miR-146a and regulating cell survival, tissue homeostasis, and T cell 585 
activation may have important implications for our understanding of the physiologic 586 
responses occurring for example during infections with helminthes parasites or allergic 587 
reactions, and possibly even in mast cell disorders such as systemic mastocytosis. 588 
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Figure Legends 733 
Figure 1. Increased tissue mast cells in mice lacking p50. A) Peritoneal lavage was 734 
performed on control and p50ko mice, and total cell numbers and percentages of mast cells 735 
(Kit+ FcεRI+), Mac-1+ and Gr-1+ cells were assessed by manual counting and FACS 736 
staining, respectively. Each dot represents one animal. B) Immunofluorescence staining of 737 
small intestine sections of control and p50ko mice. Mast cells were identified by staining with 738 
an anti-Tryptase antibody (shown, top), or an anti-Kit-antibody. At least 10 fields per tissue 739 
slide were observed and counted blindly (the operator counting the cells was not aware of the 740 
type of sample, which was coded) and the observed percentage of Tryptase + or Kit+ cells are 741 
plotted (bottom). C) Mast cell proliferation was assessed by thymidine incorporation assay. 742 
Control and p50ko mast cells were either left resting or were stimulated for 24h with IgE-Ag 743 
complexes or LPS prior addition of 3H-thymidine. Shown is one representative experiment 744 
out of three. D) To assess mast cell degranulation in response to acute stimulation in vitro, 745 
mast cells were either left untreated or were stimulated with IgE-Ag complexes or LPS for 1h 746 
prior measurement of β-N-acetylhexosaminidase release in degranulation assay. Shown is one 747 
representative experiment out of three. E) Mast cells were differentiated from C57Bl/6 and 748 
p50ko mice and injected intradermally (i.d.) in the ear pinna of KitW-sh/W-sh mice. Four weeks 749 
after injection, mast cells were sensitized by i.d. injection of IgE-anti-DNP and then 750 
challenged 24h later intravenously with DNP-HSA and Evans-blue to assess extravasation. 751 
Blue ear intensity was analyzed spectrophotometrically (OD600) after extraction with 752 
formamide. Pictures on the left show one representative experiment, and the graph shows the 753 
quantification of several experiments. Each dot represents one mouse. F) Effective mast cell 754 
reconstitution of the ear pinna performed as in E) was assessed by fixation and embedding in 755 
paraffin of the ear tissue followed by toluidine blue staining. 756 
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Figure 2. Reduced cytokine production in the absence of p50. A) Cells were either 757 
left untreated or were stimulated with IgE-Ag complexes or LPS prior analysis of IL-6 and 758 
TNFα expression by intracellular cytokine staining. B) Same as in A), except that IL-13 759 
production is shown. C) Same as in A) except that the percentage of cells positive for the 760 
indicated cytokine is provided. Each dot represents one independent experiment. D) (Top) 761 
Surface expression of FcεRIα in control and p50ko mast cells, unstimulated or stimulated 762 
with IgE and antigen for 24h to assess cell ability to upregulate FcεRIα expression. (Bottom) 763 
Expression of TLR4 on the surface of control and p50ko mast cells, unstimulated or 764 
stimulated with LPS for 3h. 765 
Figure 3. Enhanced survival and increased expression of anti-apoptotic factors in 766 
the absence of p50. Mast cells were cultured with IL-3 alone (A) or IL-3+SCF (B) prior 767 
removal of IL-3 or SCF for ~4 days. Analysis of cell death was performed by AnnexinV 768 
staining. The graph in panel A) shows the mean of four independent experiments, while panel 769 
B) is representative of at least two experiments. C) Same as in (A), except that cells were 770 
either left unstimulated or were stimulated with IgE and antigen at the time of initial IL-3 771 
withdrawal. Shown is one representative experiment out of two. D) P50ko and control cells 772 
were either left resting or were stimulated for 24h with IgE-Ag complexes (top) or LPS 773 
(bottom). Total RNA was extracted and A1 mRNA expression was assessed by qRT-PCR. 774 
Shown is one representative experiment out of four. E) Same as in D) except that expression 775 
of bcl2 was assessed. Shown is one representative experiment out four. F-G) Expression 776 
levels of bcl-XL (F) and bax (G) were analyzed by qRT-PCT in unstimulated control and p50-777 
deleted mast cells. Shown is one representative experiment out four for bax, and out of three 778 
for bcl-XL.  779 
Figure 4. MiR-146a is not expressed in mast cells in the absence of p50. A) 780 
Differentiated mast cells were either left resting or were stimulated with PMA and ionomycin 781 
 31
(P+I) for 24h prior analysis of the expression of miR-146a, miR-221 and miR27a by qRT-782 
PCR. SnoRNA202 was used as endogenous control. Shown is one representative experiment 783 
out of three. B) Same as in (A), except that cells were stimulated with either IgE and antigen 784 
(top) or LPS (bottom) for the indicated times. Shown is one representative experiment out of 785 
three. C) Mast cells were lentivirally (LV) transduced to express either miR-146a or an 786 
irrelevant hairpin as a control (shLuc). MiR-146a expression was assessed by qRT-PCR. D) 787 
Cells treated as in (C) were analyzed for apoptosis by AnnexinV staining. E) Cells treated as 788 
in (C) were lysed in Laemmli sample buffer and expression of Traf6 was analyzed by 789 
Western blot. β-tubulin was used as loading control and quantification was performed using 790 
an image reader. Shown is the ratio between the Traf6 and β-tubulin signals in one out of two 791 
independent experiments with similar results. F) Same as in (C), except that levels of 792 
expression of bcl2 were analyzed by qRT-PCR. G) Cells lentivirally transduced as in (C) 793 
were stimulated with IgE and antigen prior intracellular cytokine staining to assess IL-6 and 794 
TNFα expression. Each dot represents one independent experiment. 795 
Figure 5. Memory T cells express high levels of miR-146a, which is induced by 796 
TCR stimulation. A) Naïve CD4 T cells were isolated from the spleen and lymph nodes of 797 
C57Bl/6 or OT-II mice and differentiated to either Th1 or Th2. At day 5, cells were either left 798 
resting or were restimulated with PMA and ionomycin for 6h prior RNA extraction and qRT-799 
PCR for miR-146a (left) and intracellular cytokine staining to verify polarization (right). 800 
SnoRNA202 was used as endogenous control. B) Naïve CD4 T cells were isolated from the 801 
spleen and lymph nodes of C57Bl/6 or OT-II mice, were labeled with CFSE and stimulated 802 
with the indicated concentrations of anti-CD3 in the presence of anti-CD28 for 48h. The 803 
number of cycles was counted based on CFSE dilution (left) and miR-146a expression was 804 
evaluated in the same samples by qRT-PCR (right). C) Naïve CD4 T cells were isolated from 805 
the spleen and lymph nodes of OT-II mice, and were transferred i.v. into recipient C57Bl/6 806 
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mice prior challenge with OVA. Five and fifteen days after transfer TEM and TCM were FACS-807 
sorted (TEM: CD62Llo CD44hi CD127hi; TCM: CD62Lhi CD44hi, CD127hi) and miR-146a 808 
expression was measured by qRT-PCR. D) (Left) Same as in (C) except that OT-I naïve T 809 
cells were used and mice were challenged with either OVA or SIINFKL peptide. (Right) 810 
Purified naïve CD8 cells were stimulated in vitro with plate-bound anti-CD3 and anti-CD28 811 
for two days and further expanded up to day 6 with 10-100 U/mL of rIL-2, after which they 812 
were either left resting or were restimulated for 6h with PMA and ionomycin (P+I), prior 813 
analysis of miR-146a expression.  E) MiR-146a expression in human TH1 and TH2 clones 814 
was assessed by qRT-PCR (left). RNU48 was used as endogenous control. Clones were 815 
characterized by the expression of surface markers and by the expression of IFNγ and IL-4 816 
(right). F) Resting primary human CD4 cells were either immediately lysed in Trizol or were 817 
stimulated with plate-bound anti-CD3 and anti-CD28 for 3 and 6 days prior analysis of miR-818 
146a expression by qRT-PCR. G) Primary human CD4 T cells were sorted from peripheral 819 
blood as follows: naïve: CD4+ CD8– CD25– CD45RA+ CCR7+; TEM: CD4+ CD8– CD25– 820 
CD45RA– CCR7–; TCM: CD4+ CD8– CD25–CD45RA– CCR7+. Cells were lysed in Trizol 821 
immediately after sorting and miR-146a expression was assessed by qRT-PCR.  822 
Figure 6. MiR-146a expression in T cells led to enhanced expansion and reduced 823 
CCR7 expression upon TCR stimulation. A) (Top) Schematic of the lentiviral vector used. 824 
The control vectors expressed GFP alone or in combination with a non-targeting hairpin or an 825 
shRNA against luciferase. (Bottom) Primary human T cells (CD4+ CD45RA– CD25– CD8–) 826 
transduced with the indicated vector were sorted for GFP expression 2-5 days after 827 
transduction. Shown are cells obtained after sorting in one representative experiment. After 828 
initial experiments, TH1 (CXCR3+), TH2 (CCR4+) or TH17 (CCR6+ CCR4+) subsets were 829 
used interchangeably as provided identical results.  B) Primary human T cells transduced with 830 
either a miR-146a- or control-expressing vector were stimulated for 48h on plate-bound anti-831 
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CD3 and anti-CD28 in the presence or absence of 500U/mL IL-2, and then expanded for 6 832 
days with or without addition of exogenous IL-2. Cell number was assessed daily and plotted 833 
as fold expansion. The left panel shows one representative experiment while the right panel 834 
shows the mean result of four experiments (fold expansion at day 5 only). C) CCR7 surface 835 
expression was assessed on cells treated as in (B). Stimulated cells were homogenously 836 
CD45RA– CD25+. D) CCR7 mRNA expression was assessed by qRT-PCR in cells as in (C). 837 
E) Primary human T cells were transduced with the indicated lentiviral vectors, and CCR7 838 
mRNA expression was assessed 3-5 days after transduction. Representative of 4 independent 839 
experiments performed in various conditions (i.e. with or without exogenous IL-2, at resting 840 
state or upon restimulation with anti-CD3 and anti-CD28 for 3 days), all with comparable 841 
results. F) Primary naïve human T cells transduced with the indicated vectors were stimulated 842 
with plate-bound anti-CD3 and anti-CD28 for 5 days prior qRT-PCR to determine expression 843 
of miR-146a, CCR7, and TRAF6. Shown is one experiment out of two.  844 
Figure 7. TCM differentiation in the absence of p50 and miR-146a. A) CD8+ or B) 845 
CD4+ naïve T cells were sorted from the spleen and lymph nodes of p50ko and control mice 846 
and were either immediately lysed in Trizol or were stimulated for 2-5 days with plate-bound 847 
anti-CD3 and anti-CD28, after which they were either left resting or were restimulated with 848 
PMA and ionomycin (P+I) for 6h. RNA was extracted and expression of miR-146a assessed 849 
by qRT-PCR. C) Spleen and lymph nodes were collected from p50ko and control mice (3 850 
mice per group) and the percentage of naïve (CD62L+ CD44–), effector (CD62L– CD44+) 851 
and memory (CD62L+ CD44+) cells was evaluated in the CD4 and CD8 compartments. D) 852 
Naïve CD4 and CD8 T cells were FACS-sorted from the spleen and lymph nodes of p50ko 853 
and control mice (3 mice per group) and were stimulated for 5 days with plate-bound anti-854 
CD3 and anti-CD28, after which expression of CD44, CD62L and CD25 was assessed by 855 
FACS staining. E) Top: schematic representation of the retroviral vector used for transduction 856 
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of primary murine T cells, expressing either GFP alone or GFP and miR-146a. The insert was 857 
verified by sequencing and expression of vector-derived miR-146a evaluated in a separate 858 
transduction experiments of total wild-type CD4+ T cells (qRT-PCR graph at the bottom). 859 
Indicated below each bar are the percentages of GFP+, transduced cells. Untr.=untransduced 860 
control. F) Sorted naïve CD4+ T cells (CD62Lhi CD44lo) from p50ko mice were transduced 861 
with the indicated retroviruses 48h after initial activation with plate-bound anti-CD3 and anti-862 
CD28, and expression of CD62L and CD44 was assessed at day 5 after stimulation (day 3 863 
after transduction). Cells shown in the FACS-plots on the right were gated on the GFP+ cells. 864 
G) To assess whether changes in miR-146a expression during the first two days of T cell 865 
stimulation could be essential for the final outcome on the phenotype, which we could not 866 
investigate by using retroviruses, sorted naïve p50ko CD4+ T cells were transiently trasfected 867 
with Amaxa prior anti-CD3/ anti-CD28 stimulation. Transfection efficiency was assessed by 868 
using a non-targeting fluorescent oligo (siGLO, left panel). Expression of CD44, CD62L and 869 
CD25 was assessed at day 2, 3 and 4 after transfection. Shown is day 3 of one representative 870 
experiment out of two.  871 
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